Stock 20B BIOMARK DIAGNOSTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Biomark Diagnostics Inc.

Equities

20B

CA09073K1084

Biotechnology & Medical Research

Delayed Deutsche Boerse AG
Other stock markets
 02:18:15 2024-04-30 am EDT 		5-day change 1st Jan Change
0.173 EUR -4.42% Intraday chart for Biomark Diagnostics Inc. -1.14% +17.69%
Feb. 29 Biomark Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Feb. 28 BioMark Diagnostics Inc. Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved Communities CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 3.185 3.306 13.36 30.54 15.65 15.37
Enterprise Value (EV) 1 3.149 3.286 12.76 29.79 17.23 16.95
P/E ratio -4.21 x -6.14 x -10.8 x -26.7 x -9.98 x -8.29 x
Yield - - - - - -
Capitalization / Revenue - - 50,736,829 x - 356,209,178 x 100,126,793 x
EV / Revenue - - 48,445,990 x - 392,262,031 x 110,415,720 x
EV / EBITDA - - -10,869,811 x -29,056,266 x -13,486,708 x -9,276,188 x
EV / FCF -6.7 x -131 x -223 x -70.9 x -27 x -47.7 x
FCF Yield -14.9% -0.76% -0.45% -1.41% -3.71% -2.1%
Price to Book -3.54 x -2.71 x -30.4 x -386 x -24.6 x -13.4 x
Nbr of stocks (in thousands) 62,794 65,015 72,314 76,784 77,974 83,286
Reference price 2 0.0507 0.0509 0.1847 0.3978 0.2007 0.1845
Announcement Date 7/30/18 7/29/19 7/22/20 7/14/21 7/11/22 7/31/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales - - 0.2633 - 0.0439 0.1535
EBITDA - - -1.173 -1.025 -1.278 -1.827
EBIT 1 -0.6606 -0.5269 -1.185 -1.028 -1.284 -1.84
Operating Margin - - -450.22% - -2,922.5% -1,198.95%
Earnings before Tax (EBT) 1 -0.7267 -0.5456 -1.215 -1.094 -1.454 -1.842
Net income 1 -0.7267 -0.5456 -1.215 -1.094 -1.454 -1.842
Net margin - - -461.59% - -3,309.36% -1,200.21%
EPS 2 -0.0120 -0.008277 -0.0170 -0.0149 -0.0201 -0.0223
Free Cash Flow 1 -0.4702 -0.025 -0.0571 -0.4199 -0.6394 -0.3553
FCF margin - - -21.7% - -1,455.47% -231.49%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 7/30/18 7/29/19 7/22/20 7/14/21 7/11/22 7/31/23
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - 1.58 1.58
Net Cash position 1 0.04 0.02 0.6 0.76 - -
Leverage (Debt/EBITDA) - - - - -1.24 x -0.8644 x
Free Cash Flow 1 -0.47 -0.03 -0.06 -0.42 -0.64 -0.36
ROE (net income / shareholders' equity) 74% 51.5% 147% 422% 407% 206%
ROA (Net income/ Total Assets) -904% -762% -221% -80.8% -66.2% -104%
Assets 1 0.0804 0.0716 0.5511 1.355 2.196 1.765
Book Value Per Share 2 -0.0100 -0.0200 -0.0100 -0 -0.0100 -0.0100
Cash Flow per Share 2 0 0 0.0100 0.0100 0 0
Capex 1 0 - 0 - 0.06 0.01
Capex / Sales - - 0.3% - 134.75% 3.45%
Announcement Date 7/30/18 7/29/19 7/22/20 7/14/21 7/11/22 7/31/23
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Diagnostics & Testing

1st Jan change Capi.
BIOMARK DIAGNOSTICS INC. Stock Biomark Diagnostics Inc.
+17.69% 17.63M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-20.55% 10.81B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+47.97% 3.36B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-32.75% 2.22B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-14.15% 2.16B
VERACYTE, INC. Stock Veracyte, Inc.
-26.06% 1.55B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+19.85% 1.04B
SEEGENE, INC. Stock Seegene, Inc.
-2.62% 746M
CAREDX, INC Stock CareDx, Inc
-31.67% 425M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-43.88% 405M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. 20B Stock
  4. Financials Biomark Diagnostics Inc.